Cargando…

Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors

Purpose: Checkpoint inhibitors have significantly improved treatment of metastatic melanoma. However, 40–60% of patients do not respond to therapy, emphasizing the need for better predictive biomarkers for treatment response to immune checkpoint inhibitors. Prorammed death-ligand 1(PD-L1) expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pedersen, Jesper Geert, Madsen, Anne Tranberg, Gammelgaard, Kristine Raaby, Aggerholm-Pedersen, Ninna, Sørensen, Boe Sandahl, Øllegaard, Trine Heide, Jakobsen, Martin Roelsgaard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353055/ https://www.ncbi.nlm.nih.gov/pubmed/32486146 http://dx.doi.org/10.3390/cancers12061414

Ejemplares similares

Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
por: Pedersen, Jesper Geert, et al.
Publicado: (2022)

Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel
por: Kisistók, Judit, et al.
Publicado: (2023)

cGAS-STING pathway expression as a prognostic tool in NSCLC
por: Raaby Gammelgaard, Kristine, et al.
Publicado: (2021)

Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment
por: Demuth, Christina, et al.
Publicado: (2017)

IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
por: Hussmann, Dianna, et al.
Publicado: (2017)

Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells
por: Clement, Michelle Simone, et al.
Publicado: (2020)

Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2016)

Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC
por: Gammelgaard, Kristine Raaby, et al.
Publicado: (2018)

Regulatory dissection of the CBX5 and hnRNPA1 bi-directional promoter in human breast cancer cells reveals novel transcript variants differentially associated with HP1α down-regulation in metastatic cells
por: Vad-Nielsen, Johan, et al.
Publicado: (2016)

Day-to-day and within-day biological variation of cell-free DNA
por: Madsen, Anne Tranberg, et al.
Publicado: (2019)

A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations
por: Demuth, Christina, et al.
Publicado: (2018)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients
por: Madsen, Anne Tranberg, et al.
Publicado: (2020)

EGFR transcription in non‐small‐cell lung cancer tumours can be revealed in ctDNA by cell‐free chromatin immunoprecipitation (cfChIP)
por: Månsson, Christoffer Trier, et al.
Publicado: (2021)

Rhabdomyosarcoma in Adults: A Retrospective Analysis of Case Records Diagnosed between 1979 and 2018 in Western Denmark
por: Mäkinen, Vivi-Nelli, et al.
Publicado: (2021)

Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients
por: Winther-Larsen, Anne, et al.
Publicado: (2017)

Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience()
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2019)

Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis
por: Winther-Larsen, Anne, et al.
Publicado: (2021)

Hyponatremia as a prognostic factor in non-small cell lung cancer: a systematic review and meta-analysis
por: Sandfeld-Paulsen, Birgitte, et al.
Publicado: (2021)

Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients
por: Winther-Larsen, Anne, et al.
Publicado: (2022)

Pretreatment Albumin-to-Alkaline Phosphatase Ratio Is a Prognostic Marker in Lung Cancer Patients: A Registry-Based Study of 7077 Lung Cancer Patients
por: Sandfeld-Paulsen, Birgitte, et al.
Publicado: (2021)

A Validated Prognostic Biomarker Score for Adult Patients with Nonmetastatic Soft Tissue Sarcomas of the Trunk and Extremities
por: Maretty-Kongstad, Katja, et al.
Publicado: (2017)

The Importance of Reference Gene Analysis of Formalin-Fixed, Paraffin-Embedded Samples from Sarcoma Patients — An Often Underestimated Problem()()
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2014)

Relative mortality in soft tissue sarcoma patients: a Danish population-based cohort study
por: Maretty-Nielsen, Katja, et al.
Publicado: (2014)

Population-based Aarhus Sarcoma Registry: validity, completeness of registration, and incidence of bone and soft tissue sarcomas in western Denmark
por: Maretty-Nielsen, Katja, et al.
Publicado: (2013)

Comorbidity in Adult Bone Sarcoma Patients: A Population-Based Cohort Study
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2014)

The Prognostic Value of Serum Biomarkers in Localized Bone Sarcoma()
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2016)

A Cohort Study of Free Light Chain Ratio in Combination with Serum Protein Electrophoresis as a First-Line Test in General Practice
por: Sandfeld-Paulsen, Birgitte, et al.
Publicado: (2022)

Role of high‑sensitivity C‑reactive protein in patients with sarcoma
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2023)

Targeted Treatment of Soft-Tissue Sarcoma
por: Riskjell, Anne Iren, et al.
Publicado: (2023)

Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2011)

Macrophage Biomarkers sCD163 and sSIRPα in Serum Predict Mortality in Sarcoma Patients
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2023)

Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports
por: Thomsen, Kenneth, et al.
Publicado: (2018)

Inclusion of Metabolic Tumor Volume in Prognostic Models of Bone and Soft Tissue Sarcoma Increases the Prognostic Value
por: Pedersen, Mette Abildgaard, et al.
Publicado: (2023)

Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: A cohort study of 922 consecutive patients
por: Maretty-Nielsen, Katja, et al.
Publicado: (2014)

Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
por: Fitzgerald, Sandra, et al.
Publicado: (2023)

Expression of the EGF Family in Gastric Cancer: Downregulation of HER4 and Its Activating Ligand NRG4
por: Nielsen, Trine Ostergaard, et al.
Publicado: (2014)

A prognostic profile of hypoxia-induced genes for localised high-grade soft tissue sarcoma
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2016)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA
por: Kjær, Ina Mathilde, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4bg7d4pn91hih76libim415me1